• Home
  •  / Amicus Therapeutics

Amicus Therapeutics

  • Revenue$260.9 MFY, 2020
  • Market Capitalization$2.2 B2022-05-27

OverviewSuggest Edit

Amicus Therapeutics is a biopharmaceutical company developing oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. The Company is focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. Its technology involves the use of small molecules to restore or improve biological activity in cells by selectively binding to misfolded, unstable proteins caused by genetic mutations. It is initially targeting lysosomal storage disorders and continues to develop its pharmacological chaperone technology having built an intellectual property portfolio along with its robust clinical and preclinical pipeline.

TypePublic
Founded2002
HQPhiladelphia, PA, USMap
Websiteamicusrx.com
Employee Ratings3.3
Overall CultureC+More
View Jobs (21)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)584(+15%)
Job Openings21
Revenue (FY, 2020)$260.9 M(+44%)
Share Price (May 2022)$7.9
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Amicus Therapeutics

John F. Crowley

John F. Crowley

Chairman and Chief Executive Officer
Margaret G. McGlynn

Margaret G. McGlynn

Director
Robert Essner

Robert Essner

Director
Lynn D. Bleil

Lynn D. Bleil

Director
Burke W. Whitman

Burke W. Whitman

Director
Craig A. Wheeler

Craig A. Wheeler

Director
Show more

Amicus Therapeutics Office Locations

Amicus Therapeutics has offices in Philadelphia, Northbridge, Pointe-Claire, Paris and in 7 other locations
Philadelphia, PA, US (HQ)
3675 Market St
Northbridge, AU
21 Dorset Rd
Pointe-Claire, CA
6500 TransCanada Service Rd, 4th Floor
Paris, FR
12 Place de la Défense
München, DE
Willy-Brandt-Platz
Dublin, IE
Block 1, Blanchardstown Corporate Park, Ballycoolin Rd, Ballycoolen
Show all (11)

Amicus Therapeutics Financials and Metrics

Amicus Therapeutics Revenue

Amicus Therapeutics's revenue was reported to be $260.89 m in FY, 2020
USD

Revenue (Q1, 2021)

66.4m

Gross profit (Q1, 2021)

59.9m

Gross profit margin (Q1, 2021), %

90.2%

Net income (Q1, 2021)

(65.7m)

EBIT (Q1, 2021)

(53.1m)

Market capitalization (27-May-2022)

2.2b

Closing stock price (27-May-2022)

7.9

Cash (31-Mar-2021)

184.8m

EV

2.5b
Amicus Therapeutics's current market capitalization is $2.2 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

21.4m18.4m363.0k1.2m5.0m36.9m91.2m182.2m260.9m

Revenue growth, %

(99%)(100%)

Cost of goods sold

833.0k6.2m14.4m22.0m31.0m

Gross profit

4.1m30.7m76.8m160.3m229.8m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

4.0m5.8m7.8m10.6m39.0k456.0k475.0k293.0k2.1m4.2m7.2m10.9m16.7m21.3m20.6m34.0m44.1m48.8m60.5m62.4m67.4m66.4m

Cost of goods sold

344.0k775.0k1.1m1.8m2.6m3.1m4.3m4.1m5.4m5.6m6.6m6.7m8.4m6.5m

Gross profit

1.8m3.4m6.1m9.1m14.1m18.2m16.3m30.0m38.8m43.2m54.0m55.7m59.0m59.9m

Gross profit Margin, %

84%81%85%84%84%85%79%88%88%89%89%89%88%90%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

25.7m34.0m43.6m24.1m69.5m187.0m49.1m79.7m142.8m163.2m

Accounts Receivable

5.0m3.2m759.0k1.3m9.5m22.0m33.3m46.9m

Prepaid Expenses

5.9m2.3m5.5m2.9m2.6m19.3m16.6m20.0m29.7m

Inventories

3.4m4.6m8.4m14.0m19.6m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

25.8m22.8m24.5m28.9m24.3m26.7m23.5m30.0m27.5m41.9m19.7m28.8m249.0m19.4m23.5m63.7m33.1m44.8m37.4m64.1m114.3m73.3m201.8m96.3m220.6m166.3m123.2m164.6m210.6m184.8m

Accounts Receivable

2.0m3.8m4.3m7.2m3.2m1.3m1.0m2.1m38.0k475.0k293.0k864.0k1.9m3.8m6.0m10.8m15.1m14.2m23.0m28.7m33.7m40.6m43.0m44.8m44.9m

Prepaid Expenses

3.1m3.0m2.8m2.7m3.1m1.8m2.0m1.7m1.8m951.0k1.8m2.5m3.6m3.5m2.7m3.3m5.2m10.8m6.0m6.2m10.6m14.4m16.2m13.6m20.1m19.6m15.7m18.3m15.6m21.7m

Inventories

194.0k3.3m3.7m3.9m7.3m8.1m7.8m6.3m8.2m10.4m9.2m12.8m13.0m15.8m18.8m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(44.4m)(48.8m)(59.6m)(68.9m)(132.1m)(200.0m)(284.0m)(349.0m)(356.4m)(276.9m)

Depreciation and Amortization

1.6m1.7m1.7m1.5m1.8m3.2m3.6m4.2m4.8m8.8m

Inventories

(3.7m)(897.0k)(4.2m)(5.1m)(4.6m)

Accounts Payable

1.4m(863.0k)(613.0k)6.2m15.5m7.1m12.6m17.1m46.7m(10.6m)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(26.0m)(35.7m)(13.1m)(22.5m)(38.8m)(17.5m)(32.8m)(47.4m)(15.9m)(30.6m)(47.7m)(24.3m)(51.4m)(89.2m)(43.7m)(94.7m)(141.4m)(55.0m)(103.1m)(214.8m)(49.9m)(111.8m)(270.9m)(120.3m)(204.8m)(266.7m)(88.9m)(141.4m)(205.5m)(65.7m)

Depreciation and Amortization

864.0k1.2m420.0k862.0k1.3m439.0k889.0k1.3m412.0k808.0k1.2m508.0k861.0k1.3m673.0k1.4m2.3m823.0k1.6m2.5m969.0k1.9m3.0m991.0k2.1m3.3m1.8m3.8m6.3m1.6m

Inventories

(207.0k)(3.5m)(243.0k)(351.0k)(3.4m)(3.3m)(3.4m)(2.0m)345.0k(1.9m)(2.0m)(251.0k)1.4m2.2m741.0k

Accounts Payable

(1.3m)(192.0k)(1.3m)(641.0k)(280.0k)(2.4m)173.0k(679.0k)(987.0k)(155.0k)1.2m(551.0k)459.0k14.1m(9.8m)(8.2m)(2.9m)(1.3m)(4.3m)13.0m(10.3m)(11.8m)3.7m(8.9m)12.5m8.7m(35.3m)(23.9m)(23.4m)(40.2m)
show all
USDQ2, 2011

Financial Leverage

2 x
Show all financial metrics

Amicus Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

76/100

Learn more about our premium products
SecurityScorecard logo

Amicus Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

Amicus Therapeutics Online and Social Media Presence

Amicus Therapeutics's Trends

Embed Graph

Amicus Therapeutics Company Culture

  • Overall Culture

    C+

    76/100

  • CEO Rating

    A+

    100/100

  • Compensation

    D

    55/100

Learn more on Comparably

Amicus Therapeutics News and Updates

May 04, 2022

Amicus Therapeutics to Present at the Bank of America 2022 Healthcare Conference

PHILADELPHIA, May 04, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2022 Healthcare Conference in Las Vegas, NV on Wednesday, May 11, 2022 at 12:00 p.m. P.T.
March 16, 2022

Amicus Therapeutics Announces Positive Long-Term Data from Phase 1/2 Study of AT-GAA in Pompe Disease at the 2022 MDA Clinical & Scientific Conference

Meaningful and Durable Responses in Key Endpoints of Six-Minute Walk and Forced Vital Capacity
March 10, 2022

Amicus Therapeutics Announces Presentation and Posters at the 2022 MDA Clinical & Scientific Conference

PHILADELPHIA, March 10, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced one oral presentation and two posters highlighting its development program for Pompe disease will be included at the 2022 MDA Clinical & Scientific Conference, being held March 13-16, 2022 in N…
March 01, 2022

Amicus Therapeutics to Present at the Cowen 42nd Annual Health Care Conference

PHILADELPHIA, March 01, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 9:10 a.m. E.T.
February 24, 2022

ARYA Sciences Acquisition Corp IV and Amicus Therapeutics, Inc. Mutually Agree to Terminate Business Combination Agreement With Respect to the Acquisition of Amicus’ Gene Therapy Business Due to Market Conditions

NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- ARYA Sciences Acquisition Corp IV (NASDAQ: ARYD) (“ARYA IV”), a publicly traded special purpose acquisition company sponsored by Perceptive Advisors announced today that, due to existing market conditions, it has mutually agreed with Amicus Therapeutics,…
February 24, 2022

Amicus Therapeutics Announces Full-Year 2021 Financial Results and Corporate Updates

Galafold® Revenue Growth of 17% YoY to $306M in 2021
Show more

Amicus Therapeutics Blogs

May 10, 2022

Amicus Therapeutics Receives Notification of PDUFA Date Extensions for AT-GAA

Amicus Therapeutics Receives Notification of PDUFA Date Extensions for AT-GAA Content Import Tue, 05/10/2022 - 16:02 Amicus Therapeutics Receives Notification of PDUFA Date Extensions for AT-GAA May 10, 2022 at 4:02 PM EDT General …
May 09, 2022

Amicus Therapeutics Announces First Quarter 2022 Financial Results

Amicus Therapeutics Announces First Quarter 2022 Financial Results kevindavis Mon, 05/09/2022 - 07:00 Amicus Therapeutics Announces First Quarter 2022 Financial Results May 9, 2022 at 7:00 AM EDT General General 1Q22 Gal…
April 26, 2022

Amicus Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022

PHILADELPHIA, April 26, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, May 9, 2022 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2022.
February 11, 2021

Amicus’ AT-GAA Shows Clinically Meaningful & Significant Improvements in Both Musculoskeletal and Respiratory Measures in Late-Onset Pompe Disease Compared to Standard of Care in Pivotal Phase 3 PROPEL Study

Rolling BLA submission for AT-GAA planned for completion in Q2 and other global regulatory submissions for approval expected throughout 2021 Patients switching to AT-GAA from the approved standard of care ERT (alglucosidase alfa) walked on average 17 meters farther (p=0.046) Patients switching to
February 08, 2021

Amicus Therapeutics Presents Positive Preclinical Fabry Disease Gene Therapy Data at the 17th Annual WORLDSymposium™ 2021

Amicus Optimized Transgene Show Greater Substrate Reduction than Wild Type Construct Across All Tissues and Doses Further Validates Combining Amicus-Engineered Transgenes with Penn’s AAV Gene Therapy Technologies to Develop Next Generation Gene Therapies PHILADELPHIA, Feb.
January 05, 2021

Craig A. Wheeler

Craig A. Wheeler Matthew.Callan… Tue, 01/05/2021 - 17:44 Member of the Compensation and Leadership Committee Chair of the Science and Technology Committee Craig A. Wheeler Director Director Since January 1, 2016 …
Show more

 Amicus Therapeutics Frequently Asked Questions

  • When was Amicus Therapeutics founded?

    Amicus Therapeutics was founded in 2002.

  • Who are Amicus Therapeutics key executives?

    Amicus Therapeutics's key executives are John F. Crowley, Margaret G. McGlynn and Robert Essner.

  • How many employees does Amicus Therapeutics have?

    Amicus Therapeutics has 584 employees.

  • What is Amicus Therapeutics revenue?

    Latest Amicus Therapeutics annual revenue is $260.9 m.

  • What is Amicus Therapeutics revenue per employee?

    Latest Amicus Therapeutics revenue per employee is $446.7 k.

  • Who are Amicus Therapeutics competitors?

    Competitors of Amicus Therapeutics include Modis Therapeutics, Sanofi Genzyme and PhaseBio Pharmaceuticals.

  • Where is Amicus Therapeutics headquarters?

    Amicus Therapeutics headquarters is located at 3675 Market St, Philadelphia.

  • Where are Amicus Therapeutics offices?

    Amicus Therapeutics has offices in Philadelphia, Northbridge, Pointe-Claire, Paris and in 7 other locations.

  • How many offices does Amicus Therapeutics have?

    Amicus Therapeutics has 11 offices.